CSLLY News and Press, CSL Ltd ADR From 11/28/23

2023-11-28 14:14:56 ET More on Arcturus, CSL, etc. CSL Limited: Positive Capital Return And Earnings Growth Expectations From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key ...

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults PR Newswire Exclusive Partner in Japan , Meiji Seika Pharma advances regulatory approval ...

Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need First ...

2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...

Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment PR Newswire Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia 1 This year, the ...

2023-11-17 16:38:12 ET Summary CSL Limited might possibly embark on a new share buyback plan in the future, when its financial leverage ratio is reduced. CSL Limited is committed to allocating 10%-11% of its sales to R&D investments on a yearly basis, and this is supportive of...

CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire HEMGENIX ® , the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass. , Oct. 27,...

Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B Canada NewsWire CSL's HEMGENIX ® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON ...

2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...

2023-10-13 16:37:00 ET Summary Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands Haemonetics' Hospital product portfolio; a specialty guide...